The AHA, 340B Health, America’s Essential Hospitals, Association of American Medical Colleges, and Children’s Hospital Association yesterday filed a friend-of-the-court brief urging the U.S. Courts of Appeals for the 3rd Circuit to require drug companies to fulfill their legal obligations to provide 340B discounted drugs to eligible hospitals and health systems, regardless of whether the drugs are dispensed on site or through contract pharmacies.   
 
HHS last year sent violation letters to AstraZeneca and five other pharmaceutical companies for refusing to provide 340B discounts for drugs dispensed through contract pharmacies. The hospital groups told the court they agree with HHS’s arguments regarding the 340B statute’s meaning, the agency’s authority to enforce it, and the propriety of HHS’s violation letters. The organizations also elaborate on certain issues not already addressed in their recent friend-of-the-court brief responding to Novo Nordisk and Sanofi appeals challenging the HHS letters. 
 

Related News Articles

Headline
The United States District Court for the District of Columbia today ruled in favor of the AHA, holding that the Department of Health and Human Services…
Perspective
Forty-six days from now on Nov. 8 millions of Americans will cast their ballots and exercise their most sacred right – the right to vote. That means that for…
Headline
The U.S. District Court for the District of Columbia should reject the Department of Health and Human Services’ request to devise on its own timeline a remedy…
Blog
In July, the Centers for Medicare & Medicaid Services published its annual outpatient prospective payment system regulation, in which the agency proposed a…
Headline
Commenting today on the Centers for Medicare & Medicaid Services’ proposed calendar year 2023 payment rule for hospital outpatients and ambulatory surgical…
Headline
The U.S. District Court for the District of Columbia should vacate the 2022 outpatient prospective payment system rule insofar as it sets a payment rate for…